Co-Division Head, Dr. Chew Wei MBBS [HK] FRCOG [ENG] Memorial Chair in Gynaecologic Oncology
6048754268

Biography

Dr. Jessica McAlpine was born and raised in Vancouver. She did her medical training in the US, returning in 2006 to take a position at UBC and BC Cancer. Dr. McAlpine has been appointed the Dr. Chew Wei Memorial Chair in Gynaecologic Oncology and Heads the Division of Gynaecologic Oncology with Dr. Sarah Finlayson.  She is part of the OVCARE research team (British Columbia’s Gynecological Cancer Research group), Director of the OVCARE Tissue Bank and recipient of a CIHR New Investigator Award (2013-2018) and BC Cancer Foundations Clinician Scientist Award in (2016-2021). Her research focuses on molecular subtypes of endometrial, ovarian and vulvar cancers, and the prevention of ovarian cancers.

Publications

McAlpine JN, Wiegand KC, Vang R, Ronnett BM, Adamiak AK. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer, 2009. Dec 10;9:433. PMID: 20003286

Kortman U, McAlpine JN, Xue H, Guan J, Ha G, Tully S, Shafait S, Lau A, Cranston AN, O’Conner MJ, Huntsman DG, Wang Y, Gilks CB. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin Cancer Res, 2011 Feb 15; 17(4):783-91. PMID: 21097693

McAlpine JN, El-Hallani S, Lam SF, Kalloger SE; Luk M, Huntsman DG, MacAulay, C, Gilks CB, Miller DM, Lane PM. Autofluorescence imaging can identify preinvasive or clinically occult lesions in fallopian tube epithelium: a promising step towards screening and early detection. Gynecol Oncol 2011 Mar; 120(3):385-92. PMID: 21237503

McAlpine JN, Vermorken JB, Wenzel LB. Survivorship as an element of clinical trials in ovarian cancer. Int J Gynecol Cancer 2011 May;21(4):788-92. PMID: 21543942

McAlpine JN, Gilks CB. Human epidermal growth factor receptor 2 overexpression and amplification in mucinous tumours of ovary Histopathology, 2011 Jun;58(7):1173-4. PMID: 21707717

Brotto L, Branco N, Dunkley C, McCullum M, McAlpine JN. Risk-reducing bilateral salpingo-oophorectomy and sexual health: a qualitative study. J Obst Gynaecol Canada, 2012 Feb;34(2):172-8. PMID: 22340066

Brotto, L, Erskine Y, Carey M, Ehlen T, Finlayson S, Heywood M, Kwon J, Thomson S, Stuart G, McAlpine JN, Miller DM. A brief mindfulness-based cognitive behavioral intervention improves sexual functioning versus wait-list control in women treated for gynecologic cancer. Gynecol Oncol 2012 May;125(2):320-5. PMID: 22293042

McAlpine JN, Porter H, Kobel M, Nelson BH, Prentice LM, Kalloger SE, Senz J, Milne K, Ding J, Shah SP, Huntsman DG, Gilks CB. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Mod Pathol. 2012 May;25(5):740-50 PMID: 22282309

Tone A, Salvador S, Finlayson SJ, MD, Tinker AV, Kwon JS, Lee C, Cohen T, Ehlen T, Lee M, Carey MS, Heywood M, Pike J,Hoskins P, Stuart GC, Swenerton KD,Huntsman DG, Gilks CB, Miller DM, McAlpine, JN. The role of the fallopian tube in ovarian cancer. Clin Adv Hematol Oncol 2012 May;10(5):296-306. PMID: 22706539

Schrader I, Hurlburt J, Gilks CB, Huntsman DG, McAlpine JN. Germline mutations in BRCA1 and BRCA2 in ovarian cancer: utility of a histology-based referral strategy. Obst Gynecol, 2012 Aug;120 (2 Pt 1):235-40. PMID: 22776961

McConechy MK, Ding J, Cheang MC, Wiegand KC, Senz J, Tone AA, Yang W, Prentice LM, Tse K, Zeng T, McDonald H, Schmidt AP, Mutch DG, McAlpine JN, Hirst M, Shah SP, Lee CH, Goodfellow PJ, Gilks CB, Huntsman DG. Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol. 2012 Sep; 228(1):20-30. PMID: 22653804 

Bashashati A, Ha G, Tone A, Ding J, Prentice LM, Roth A, Rosner J, Shumansky K, Kalloger S, Senz J, Yang W, McConechy M, Melnyk N, Anglesio M, Luk MT, Tse K, Zeng T, Moore R, Zhao Y, Marra MA, Gilks B, Yip S, Huntsman DG, McAlpine JN, Shah SP. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol. 2013 Sep;231(1):21-34. PMID: 23780408

Anglesio MS, Kommoss S, Tolcher MC, Clarke B, Galletta L, Porter H, Damaraju S, Fereday S, Winterhoff B, Kalloger SE, Senz J, Yang W, Steed H, Ferguson S, Teoman A, Allo G Garcia J, Schoolmeester JK, Shaw P, Bakkum-Gamez J, Tinker A, Bowtell D, Huntsman DG, Gilks CB, McAlpine JN. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol. 2013 Jan 1;229(1):111-20. PMID: 22899400

Teng FF, Kalloger SE, Brotto, LA, McAlpine JNDeterminants of quality of life in ovarian cancer survivors: A pilot study. J Obstet Gynaecol Can. 2014 Aug 31;36(8):708-15. PMID: 25222166

McAlpine JN, Hanley GE, Woo MMM, Tone AE, Rozenberg N, Heywood MS, Kaye SH, Kwon JS, Ehlend TG, Carey MS, Mazgani M, Stuart GC, Swenerton KD, Gilks CB, Finlayson SJ, Huntsman DG, Miller DM. Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. Am J Obstet Gynecol. 2014 May;210(5):471.e1-11. PMID: 24412119

Gleicher N, McAlpine JN, Gilks CB, Kushnir VA, Lee HJ, Wu Y-G, Lazzaroni-Tealdi E, Barad DH. Absence of BRCA/FMR1 Correlations in Women with Ovarian Cancers. PLOS One 2014 Jul 18;9(7):e102370. PMID: 25036526

Ha G, Roth A, Khattra J, Ho J, Yap D, Prentice LM, Melynk N, McPherson A, Bashashati A, Laks E, Biele J, Ding J, Le A, Rosner J, Shumansky K, Marra MA, Gilks CB, Huntsman DG, McAlpine JN, Aparicio S, Shah SP. TITAN: Inference of copy number architectures in clonal cell populations from tumor whole genome sequence data. Genome Res. 2014 Nov 1;24(11):1881-93. PMID: 25060187

Joly F, McAlpine JN, Nout RA, Avall-Lundqvist E, Friedlander ML, on behalf of the Gynecologic Cancer Intergroup (GCIG). Quality of life and patient-reported outcomes in endometrial cancer clinical trials: a call for action! Int J Gynecol Cancer. 2014 Nov 1;24(9):1693-9. PMID: 25340294

McAlpine JN, Greimel E, Brotto LA, Nout RA, Shash E, Avall-Lundqvist E, Friedlander ML, Joly F, on behalf of the Gynecologic Cancer Intergroup (GCIG). Quality of Life research in endometrial cancer: what is needed to advance progress in this disease site? Methodological considerations from the Gynecologic Cancer InterGroup Symptom Benefit Working Group brainstorming session, Leiden 2012. Int J Gynecol Cancer. 2014 Nov 1;24(9):1686-92. PMID: 25340293

McAlpine JN, Lisonkova S, Joseph KS, McComb P. Pelvic inflammation and the pathogenesis of ovarian cancer: a cohort study. Int J Gynecol Cancer. 2014 Oct 1;24(8):1406-13. PMID: 25191876

Singh N, Leen SL, Han G, Faruqi A, Kokka F, Rosenthal A, Jiang J, Kim R, McAlpine JN, Gilks CB. Expanding the morphologic spectrum of differentiated VIN (dVIN) through detailed mapping of cases with p53 loss. Am J Surg Pathol. 2015 Jan 1;39(1):52-60. PMID: 25025443

Kwon JS, McAlpine JN, Hanley G, Finlayson S, Cohen T, Miller DM, Gilks CB, Huntsman DG. Costs and benefits of opportunistic salpingectomy as an ovarian cancer prevention strategy. Obstet Gynecol. 2015 Feb 1;125(2):338-45. PMID: 25568991

Pearce CL, Stram DO, Ness RB, Stram DA, Roman LD, Templeman C, Menon U, Fasching PA, Doherty JA, Modugno F, Schildkraut JM, Rossing MA, McAlpine JN, Huntsman D, Wu AH, Berchuck A, Pike MC, Pharoah PDP. Population distribution of lifetime risk of ovarian cancer in the United States Cancer Epidemiol Biomarkers Prev. 2015 Apr 1;24(4):671-6. PMID: 25623732

Mackenzie R, Kommoss S, Winterhoff BJ, Kipp BR, Garcia JJ, Voss J, Halling K, Karnezis A, Senz J, Yang W, Prigge ES, Reuschenbach M, Doeberitz MV, Gilks BC, Huntsman DG, Bakkum-Gamez J, McAlpine JN, Anglesio MS. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. BMC Cancer. 2015 May 19;15(1):1. PMID: 25986173

McConechy MK, Talhouk A, Li-Chang HH, Leung S, Huntsman DG, Gilks CB, McAlpine JN. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas. Gynecol Oncol. 2015 May 31;137(2):306-10. PMID: 25636458

Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, Yang W, Senz J, Boyd N, Karnezis AN, Huntsman DG, Gilks CB, McAlpine JN. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015 Jul 14;113(2):299-310. PMID: 26172027

Nelson BH, McAlpine JN. The more tumors change, the more they stay tame: Do T cells keep POLE ultramutated endometrial carcinomas in check? Gynecol Oncol. 2015 Jul;138(1):1. PMID: 26072691

Burleigh A, Talhouk A, Gilks CB, McAlpine JN. Clinical and pathological characterization of endometrial cancer in young women: identification of a cohort without classical risk factors. Gynecol Oncol. 2015 Jul 31;138(1):141-6. PMID: 25870916

Hoang LN, McConechy MK, Kobel M, Anglesio M, Senz J, Maassen M, Kommoss S, Meng B, Postovit L, Kelemen LE, Staebler A, Brucker S, Kramer B, McAlpine JN, Gilks CB, Huntsman DG, Lee CH. Polymerase epsilon exonuclease domain mutations in ovarian endometrioid carcinoma. Int J Gynecol Cancer. 2015 Sep 1;25(7):1187-93. PMID: 26166557

Fujiwara K, McAlpine JN, Lheureux S, Matsumura N, Oza AM. Paradigm shift in the management strategy for epithelial ovarian cancer. Am Soc Clin Oncol Educ Book. 2016;35:e247-57. PMID: 27249730

Bernardini MQ, Gien LT, Lau S, Altman AD, Gilks B, Ferguson, SE, Kobel M, Soumelian V, Wesa M, Cameron, A, Nelson G, Han G, Clarke B, Ho TC, Panzarella T, Atenafu, EG, McAlpine JN. Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC). Gynecol Oncol. 2016 Apr 30;141(1):148-54. PMID: 26854651

McAlpine JN, Tone AA, Hanley GE. Opportunistic salpingectomy: we chose to act, not wait. J Obstet Gynaecol Can. 2016 May;38(5):425-7. PMID: 27261215

McConechy MK, Talhouk A, Leung S, Chiu D, Yang W, Senz J, Reha-Krantz LJ, Lee CH, Huntsman DG, Gilks CB, McAlpine JN. Endometrial carcinomas with POLE exonuclease domain mutations have a favorable prognosis. Clin Cancer Res. 2016 Jun 15;22(12):2865-73. PMID: 26763250

Roth A, McPherson A, Laks E, Biele J, Yap D, Wan A, Smith MA, Nielsen CB, McAlpine JN, Aparicio S. Bouchard-Cote A, Shah SP. Clonal genotype and population structure inference from single-cell tumor sequencing. Nat Methods. 2016 Jul:13(7);573-6. PMID: 27183439

McPherson A, Roth A, Laks E, Masud T, Bashashati A, Zhang AW, Ha G, Biele J, Yap D, Wan A, Prentice LM, Khattra J, Smith MA, Nielsen CB, Mullaly SC, Kalloger S, Karnezis A, Shumansky K, Siu C, Rosner J, Chan HL, Ho J, Melnyk N, Senz J, Yang W, Moore R, Mungall AJ, Marra MA, Bouchard-Cote A, Gilks CB, Huntsman DG, McAlpine JN, Aparicio S, Shah SP. Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nat Genet. 2016 Jul;48(7):758-67. PMID: 27182968

Cheng AS, Karnezis AN, Jordan S, Singh N, McAlpine JN, Gilks CB. Immunostaining allows for accurate subclassification of vulvar squamous cell carcinoma into HPV-associated and HPV-independent cases. Int J Gynecol Pathol. 2016 Jul 1;35(4):385-93. PMID: 26630231

McAlpine JN, Temkin SM, Mackay HJ. Endometrial cancer: not your grandmother’s cancer. Cancer. 2016 Sep 15;122(18):2787-98. PMID: 27308732

Talhouk A, Hoang LN, McConechy MK, Nakonechny Q, Leo J, Cheng A, Leung S, Yang W, Lum A, Kobel M, Lee CH, Soslow RA, Huntsman DG, Gilks CB, McAlpine JN. Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: earlier prognostic information to guide treatment. Gynecol Oncol. 2016 Oct;143(1):46-53. PMID: 27421752

Hanley GE, McAlpine JN, Pearce CL, Miller D. The performance and safety of bilateral salpingectomy for ovarian cancer prevention in the United States. Am J Obstet Gynecol. 2016 Nov 1. pii: S0002-9378(16)30971-1. PMID: 27810554

McAlpine JN, Kim R. Akbari A, Eshraugh S, Knebel, K, Prigge E, Jordan S, Singh N, Miller DM, Reuschenbach M, Gilks CB. HPV-independent differentiated vulvar intraepithelial neoplasia (dVIN) is associated with an aggressive clinical course Int J Gynecol Path. 2017 Mar 17. [Epub ahead of print] PMID: 28319571

Talhouk A, McAlpine JN. New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care. Gynecol Oncolo Res Pract. 2016 Dec 13;3:14. PMID: 27999680

McAlpine JN, Leon-Castillo A, Bosse T. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. J Pathol. 2018. Jan 17. PMID: 29344951

Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J, Boyd N, Pike J, Anglesio M, Kwon JS, Karnezis AN, Huntsman DG, Gilks CB, McAlpine JN. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017 Mar 1;123(5):802-813. PMID: 28061006

Hoang LN, Kinloch MA, Leo JM, Grondin K, Lee CH, Ewanowich C, Kobel M, Cheng A, Talhouk A, McConechy M, Huntsman DG, McAlpine JN, Soslow RA, Gilks CB. Interobserver agreement in endometrial carcinoma histotype diagnosis varies depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup. Am J Surg Pathol. 2017 Feb;41(2):245-252. PMID: 28079598

Karnezis AN, Leung S, Cheng A, Miller D, Talhouk A, Gilks CB, McAlpine JN. HPV-independent vulvar squamous cell carcinoma has a worse prognosis than HPV-associated disease: a retrospective cohort study. Laboratory Investigation. 2017 Feb; 97: 293A-293A. PMID: 28257152

Hanley GE, McAlpine JN, Pearce CL, Miller D The performance and safety of bilateral salpingectomy for ovarian cancer prevention in the United States Am J Obstet Gynecol. 2017 Mar;216(3):270.e1-270.e9. PMID: 27810554 

Wang YW, Bashashati A, Anglesio MS, Cochrane DR, Grewal DS, Ha G, McPherson A, Horlings HM, Karnezis AN, Shumansky K, Siu C, McConechy MK, Li-Chang H, Tone A, Provencher D, de Laurantaye M, Okamoto A, Yanagida S, Yanaihara N, Saito M, Mugall A, Moore R, Marra M, Gilks CB, Mes-Masson A, McAlpine JN, Aparicio S, Huntsman D, Shah SP. Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes. Nat Genet. 2017 Jun;49(6):856-865. PMID: 28436987

Proctor L, Pradhan M, Leung S, Cheng A, Lee CH, Soslow RA, Gilks CB, Talhouk A, McAlpine JN, Danielsen HE, Hoang LN. Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer. Gynecol Oncol. 2017 Sep;146(3):596-602. PMID: 28647100

McAlpine JN, Leung SC, Cheng A, Miller D, Talhouk A, Gilks CB, Karnezis AN. Human papillomavirus (HPV) ‐ independent vulvar squamous cell carcinoma has a worse prognosis than HPV‐associated disease: a retrospective cohort study. Histopathology. 2017 Aug;71(2):238-246. PMID 28257152

Cochrane DR, Tessier-Cloutier B, Lawrence KM, Nazeran T, Karnezis AN, Salamanca C, Cheng AS, McAlpine JN, Hoang LN, Gilks CB, Huntsman DG. Clear cell and endometrioid carcinomas: are their differences attributable to distinct cells of origin? J Pathol. 2017 Sep;243(1):26-36. PMID: 28678427

Karnezis AN, Leung S, Magrill J, McConechy MK, Yang W, Chow C, Kobel M, Lee CH, Huntsman DG, Talhouk A, Kommoss F, Gilks CB, McAlpine JN. Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification. J Pathol Clin Res. 2017 Oct 14;3(4):279-293. PMID: 29085668

McAlpine JN, Kim SY, Akbari A, Eshragh S, Reuschenbach M, von Knebel Doeberitz M, Prigge ES, Jordan S, Singh N, Miller DM, Gilks CB. HPV-independent Differentiated Vulvar Intraepithelial Neoplasia (dVIN) is Associated With an Aggressive Clinical Course Int J Gynecol Pathol. 2017 Nov;36(6):507-516. PMID: 28319571

Hanley GE, Rozenberg NMK, McAlpine JN. Risk-reducing Surgery in Women at Low Lifetime Risk of Developing Ovarian Carcinoma: Opportunistic Salpingectomy Clin Obstet Gynecol. 2017 Dec;60(4):758-770. PMID: 28957952

McAlpine JN, Leon-Castillo A, Bosse T. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses J Pathol. 2018. Jan 17

Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, Britton H, Kommoss F, Grevenkamp F, Karnezis A, Yang W, Lum A, Kramer B, Taran F, Staebler A, Lax S, Brucker SY, Huntsman DG, Gilks CB, McAlpine JN*, Talhouk A*. Final Validation of the ProMisE Molecular Classifier for Endometrial Carcinoma in a Large Population-based Case Series. Ann Oncol. 2018 May 1;29(5):1180-1188

Hanley GE, McAlpine JN, Miller D, Huntsman D, Schrader KA, Blake Gilks C, Mitchell G. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention BMC Cancer. 2018 Mar 5;18(1):254. 

Bosse T, Nout RA, McAlpine JN, McConechy MK, Britton H, Hussein YR, Gonzalez
C, Ganesan R, Steele JC, Harrison BT, Oliva E, Vidal A, Matias-Guiu X, Abu-Rustum NR, Levine DA, Gilks CB, Soslow RA
Molecular Classification of Grade 3
Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.
Surg Pathol. 2018 May;42(5):561-568.

Zhang AW, McPherson A, Milne K, Kroeger DR, Hamilton PT, Miranda A, Funnell T, Little N, de Souza CPE, Laan S, LeDoux S, Cochrane DR, Lim JLP, Yang W, Roth A, Smith MA, Ho J, Tse K, Zeng T, Shlafman I, Mayo MR, Moore R, Failmezger H, Heindl
A, Wang YK, Bashashati A, Grewal DS, Brown SD, Lai D, Wan ANC, Nielsen CB,
Huebner C, Tessier-Cloutier B, Anglesio MS, Bouchard-Cote A, Yuan Y, Wasserman
WW, Gilks CB, Karnezis AN, Aparicio S, McAlpine JN, Huntsman DG, Holt RA, Nelson
BH, Shah SP.
Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. Cell
2018 Jun 14;173(7):1755-1769.e22

Kim SY, Tessier-Cloutier B, Cochrane, D, Britton H, Storness-bliss C, Lum A, Senz J, Lee CH, Hoang L, McAlpine J. Characterization of clear cell carcinoma of the endometrium: molecular subtype assignment to inform treatment decisions and improve outcomes. From Oral presentation at 39th Gynecologic Oncology of Canada, Victoria, BC, June 28-30, 2018 

Hanley GE, Kwon JS, Finlayson SJ, Huntsman DG, Miller D, McAlpine JN Extending the safety evidence for opportunistic salpingectomy in prevention of ovarian cancer: a cohort study from British Columbia, Canada Am J Obstet Gynecol. 2018 Aug;219(2):172.e1-172.e8. PMID: 29852159

Talhouk A, Derocher H, Schmidt P, Leung S, Milne K, Gilks B, Anglesio MS, Nelson BH, McAlpine JN Clin Cancer Res 2018. Dec6 Epub PMID: 30523022

Britton H, Huang L, Lum A, Leung S, Shum K, Kale M, Burleigh A, Senz J, Yang W, McConechy M, Kommoss S, Brucker S, Talhouk A, Gilks CB, McAlpine JN. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma. Gynecol Oncol. 2019 Jun;153(3):487-495. doi: 10.1016/j.ygyno.2019.03.098. Epub 2019 Mar 25. pii: S0090-8258(19)30271-9 PMID: 30922603

Talhouk A, Derocher H, Schmidt P, Leung S, Milne K, Gilks B, Anglesio MS, Nelson BH, McAlpine JN. Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma. Clin Cancer Res. 2019 Apr 15;25(8):2537-2548. (2018. Dec6 Epub) PMID: 30523022.

Reijnen C, Kusters-Vandevelde HVN, Prinsen CF, Massuger LFAG, Snijders MPML, Kommoss S, Brucker SY, Kwon JS, McAlpine JN, Pijnenborg JMA. Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer. Gynecol Oncol. 2019 Jul;154(1):124-130. doi: 10.1016/j.ygyno.2019.03.097. Epub 2019 May 15. PMID: 31103324 

McAlpine JN, Gilks CB. Precision medicine in endometrial cancer Gynecol Oncol. 2019 Sep;154(3):451-453. doi: 10.1016/j.ygyno.2019.08.001. No abstract available. PMID: 31472758

Zhang AW, O’Flanagan C, Chavez EA, Lim JLP, Ceglia N, McPherson A, Wiens M, Walters P, Chan T, Hewitson B, Lai D, Mottok A, Sarkozy C, Chong L, Aoki T, Wang X, Weng AP, McAlpine JN, Aparicio S, Steidl C, Campbell KR, Shah SP Probabilistic cell-type assignment of single-cell RNA-seq for tumor microenvironment profiling. Nat Methods. 2019 Oct;16(10):1007-1015. doi: 10.1038/s41592-019-0529-1. Epub 2019 Sep 9. PMID: 31501550

O’Flanagan CH, Campbell KR, Zhang AW, Kabeer F, Lim JLP, Biele J, Eirew P, Lai D, McPherson A, Kong E, Bates C, Borkowski K, Wiens M, Hewitson B, Hopkins J, Pham J, Ceglia N, Moore R, Mungall AJ, McAlpine JN; CRUK IMAXT Grand Challenge Team, Shah SP, Aparicio S Dissociation of solid tumor tissues with cold active protease for single-cell RNA-seq minimizes conserved collagenase-associated stress responses. Genome Biol. 2019 Oct 17;20(1):210. doi: 10.1186/s13059-019-1830-0.

A Leon-Castillo, H Briton, MK. McConechy, JN McAlpine, R Nout, S Kommos, SY Brucker, JW Carlson, E Epstein, TT Rau, T Bosse, DN Church, CB Gilks. Interpretation of somatic POLE mutations in endometrial carcinoma. J Pathol. 2020 Mar;250(3):323-335. PMID: 31829442. doi: 10.1002/path.5372. Epub 2020 Jan 29

A Plotkin, B Kuzeljevic2, V.De Villa, E.F. Thompson, CB. Gilks, B Clarke, M Koebel, JN McAlpine Inter-laboratory concordance of ProMisE molecular classification of endometrial carcinoma based on endometrial biopsy specimens Int J Gynecol Pathololgy No. IJGP19-3986 

L Proctor, L Hoang, J Moore, S Leung, B Gilks, E Thomson, D. Natesan, J. Chino, CB. GIlks, JN McAlpine. Association of human papilloma virus status and response to radiotherapy in vulvar squamous cell carcinoma. Int J Gynecol Cancer. 2020 Jan;30(1):100-106. doi: 10.1136/ijgc-2019-000793. Epub 2019 Nov 25. PMID: 31771962

A Leon-Castillo, E Gilvazquez, R Nout, Smit VT, JN McAlpine, M McConechy, S Kommoss, SY Brucker, JW Carlson, E Epstein, TT. Rau, R Soslow, R Ganesan, X Matias-Guiu, E Oliva, B Harrison, DN Church, B Gilks, T Bosse. Clinicopathological and molecular characterisation of ‘multiple-classifier’ endometrial carcinomas. J Pathol. 2020 Mar;250(3):312-322. PMID: 31829447. 

Kim SY, Tessier Cloutier B, Leung S, Cochrane D, Britton H, Pina A, Storness-Bliss C, Farnell D, Huang L, Shum K, Lum A, Senz J, Lee CH, Gilks CB, Hoang L, McAlpine JN. Molecular subtypes of clear cell carcinoma of the endometrium: opportunities for prognostic and predictive stratification. Gyn Onc, July 2020.

Sengal AT, Patch AM, Snell CE, Smith DS, Leung SCY, Talhouk A, Williams ED, McAlpine JN, Pollock PM. FGFR2c Mesenchymal Isoform Expression Is Associated with Poor Prognosis and Further Refines Risk Stratification within Endometrial Cancer Molecular Subtypes. Clin Cancer Res. 2020 May 15. doi: 10.1158/1078-0432.CCR-19-4088. Online ahead of print. PMID: 32414751

Cochrane DR, Campbell KR, Greening K, Ho GC, Hopkins J, Bui M, Douglas JM, Sharlandjieva V, Munzur AD, Lai D, DeGrood M, Gibbard EW, Leung S, Boyd N, Cheng AS, Chow C, Lim JLP, Farnell DA, Kommoss S, Kommoss F, Roth A, Hoang L, McAlpine JN, Shah SP, Huntsman DG. Single cell transcriptomes of normal endometrial derived organoids uncover novel cell type markers and cryptic differentiation of primary tumours. J Pathol. 2020 Jul 19. doi: 10.1002/path.5511. Online ahead of print. PMID: 32686114

Obermair A, Baxter E, Brennan DJ, McAlpine JN, Muellerer JJ, Amant F, van Gent MDJM, Coleman RL, Westin SN, Yates MS, Krakstad C, Janda M. Fertility-sparing treatment in early endometrial cancer: current state and future strategies. Obstet Gynecol Sci. 2020 Jul;63(4):417-431. doi: 10.5468/ogs.19169. Epub 2020 Jul 8.PMID: 32689770

Krämer P, Talhouk A, Brett MA, Chiu DS, Cairns ES, Scheunhage DA, Hammond RF, Farnell D, Nazeran TM, Grube M, Xia Z, Senz J, Leung S, Feil L, Pasternak J, Dixon K, Hartkopf A, Krämer B, Brucker S, Heitz F, du Bois A, Harter P, Kommoss F, Sinn HP, Heublein S, Kommoss F, Vollert HW, Manchanda R, de Kroon CD, Nijman HW, de Bruyn M, Thompson EF, Bashashati A, McAlpine JN, Singh N, Tinker AV, Staebler A, Bosse T, Kommoss S, Köbel M, Anglesio MS. Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma. Clin Cancer Res. 2020 Jul 31:clincanres.1268.2020. doi: 10.1158/1078-0432.CCR-20-1268PMID: 32737030


For a full list of publications please contact Dr. McAlpine directly.

Grants

Canadian Institutes of Health Research (CIHR)

Genomic disruption in high-grade serous ovarian carcinomas: Steady state or continuous drift? 

 C

 Operating Grant

$563,000 

2011/06 – 2015/05

McAlpine JN, Shah SP 

Huntsman DG, Gilks CB

VGH Foundation

Ovarian carcinoma from precursor lesion to prevention (PTP) 

 $300,000.00 

$300,000 

2012/06 – 2015/06

Huntsman DG, McAlpineJN

Gynecologic Cancer Initiative-Clinical Trials Group

ProMisE-driven care in endometrial carcinoma-prospective trial

C

Project Grant

$104,000

2019-2021

McAlpine JN

Holloway C, Bachand F, Kumar A, Thompson E, Ko J, Ye A, Raziee H, Kwon J, Talhouk A

Canadian Institute of Health Research

Pre-operative Risk Stratification in Endometrial Cancer to Inform Surgical Management

C

Project Grant

$263,925

2020-2023

Talhouk, A

McAlpine JN

Gilks, CB

Huntsman DG
Hanley G

Terry Fox Research Institute

CIHR Team in Genomics of Frome Fruste Tumours: New vistas on cancer biology and treatment 

 C

 Project Grant

$7,500,000 

2013/07 – 2019/07

Huntsman D, Aparicio S, Hansen C

McAlpine J, Tinker A, Clarkson P, Schaeffer D

Carraresi Foundation OVCARE Research Grant

Response to Primary Radiation in HPV-Associated and HPV-Independent Locally Advanced Vulvar Squamous Cell Cancers 

 C

 

$7,080 

2017/06 – 2019/06

Lily Proctor 

McAlpine J

Canadian Institute of Health Research

Multimodal optical imaging of the fallopian tubes 

 C

  Impact Grant

$378,675 

2017/10 – 2020/09

Lane P

MacAulay C, McAlpine JN

Canadian Cancer Society Research Institute 

The determinants of drug response in high grade serous ovarian cancer: a single cell population genetics approach 

 C

 Impact Grant

$1,250,000 

2018/01 – 2023/12

Shah S & McAlpine J

Aparicio S, Huntsman D, Bouchard-Cote A

Michael Smith Foundations for Health Research-REACH award

Biologically informed ovarian cancer prevention: Promoting education and awareness 

 C

 Current funding

$10,000 

2018/06 – 2019/06

McAlpine JNHuntsman DG

Lee, S

Michael Smith Foundations for Health Research-Innovation to commercialization (I2C)

Molecular classification for stratification and improved clinical management
of endometrial cancers

 C

 Current funding

$300,000 

2018/07 – 2020/07

McAlpine JN

Gilks CB, Aline T

Sumiko Kobayashi Marks Memorial OVCARE Research Grants supported by the VGH & UBC Hospital Foundation

Refining the Clinical and Molecular Landscape of Vulvar Squamous Cell Carcinomas: Not a Single Disease Anymore

 C

 

$19,678 

2019/06 – 2021/05

Hoang LN

McAlpineJN, Proctor L, Thompson E

Canadian Institute for Health Research-Project Grant

The effectiveness and cost effectiveness of opportunistic salpingectomy for ovarian
cancer prevention

 C

 

$302,176 

2019/07 – 2022/07

Hanley G

McAlpineJN Huntsman DG, Gilks CB, Kwon J, Talhouk A, Kotsopoulos J

 

Canadian Institute of Health Research 

PrOTYPE: An Enabling Technology to Improve Ovarian Cancer Care 

 C

 Proof of Principle I grant

$154,829 

2013/01 – 2015/12

Huntsman, DG

McAlpine JN, Anglesio M

Canadian Cancer Society Research Institute 

Contextual genomics: the foundation of subtype specific approaches to ovarian cancer control 

 C

 Impact grant

$1,996,690 

2013/02 – 2018/01

Huntsman D

McAlpine J,Shah S, Carey M, Gilks B, Miller D, Tinker A, Yong P, Morin R, Hoskins P, Cullis P, Anglesio M.

British Columbia Cancer Foundation

SMART cancer project: Shared access medicine, an approach to rare tumors 

 C

 Research Award

$264,100 

2013/06 – 2015/05

McAlpine JN, Tinker AV

BC Cancer Foundation (BCCF) Sarabjit Gill Memorial Fund

Understanding intra-tumoral heterogeneity within endometrial cancers 

 NC

 Research Award 

$80,000 

2013/07 – 2015/06

McAlpine JN

National Institute of Health 

Mechanisms of Prevention of Ovarian Cancer by Oral Contraceptives 

 C

 Project Grant

$52,704 

2013/07 – 2015/07

Huntsman D, Pearce CL

McAlpine JN, et al

Terry Fox Research Institute

CIHR Team in Genomics of Frome Fruste Tumours: New vistas on cancer biology and treatment 

 C

 Project Grant

$7,500,000 

2013/07 – 2019/07

Huntsman D, Aparicio S, Hansen C

McAlpine J, Tinker A, Clarkson P, Schaeffer D

Cancer Research Society

Circulation tumor DNA mutations in endometrial and ovarian cancer patients can be used to guide clinical management 

 C

 Operating grant

$119,147 

2014/06 – 2016/05

McAlpine J

Gilks CB, Huntsman D, Shah S

Canadian Cancer Society Research Institute 

A population-based assessment of an ovarian cancer prevention program 

 C

 Prevention research grant

$324,612 

2014/08 – 2017/07

McAlpine J, Huntsman D

Coldman A, Gilks B, Miller D, Mitchell G

Vancouver Coastal Health Research Institute

Subclassification of vulvar cancer based on HPV status / p16 immunostaining: assessment
of clinical utility in a large retrospective cohort, with independent validation 

 C

 Innovation and Translation award

$15,966 

2015/09 – 2017/08

McAlpine JN, Gilks CB

Canadian Cancer Society Research Institute

Fixed tissue proteomics (FTP) applied to create a pragmatic clinical decision aid for endometrial cancer 

 C

 Innovation grant

$200,000 

2016/02 – 2018/02

McAlpine J

Canadian Institutes of Health Research

PROMISE: A proactive molecular- based classification tool to improve endometrial cancer management 

 C

 Proof of Principle I (POP1) grant

$160,000 

2016/06 – 2017/06

McAlpine J

Michael Smith Foundation for Health Research

Knowledge transfer of current molecular research in endometrial cancer to pathologists, gynecologists, family practitioners and other end-users in British Columbia 

 C

 Collaborating and Convening Award

$15,000 

2017/01 – 2018/01

McAlpine J

Schrader K, Miller D, Tinker A, Talhouk A, Huntsman, D, Gilks B

University of British Columbia -Division of Gynecologic Oncology

Practical methodologies for the identification of Synchronous Endometrial and Ovarian Carcinomas (SEOs) to improve outcomes 

 C

 Research Award 

$20,000 

2017/03 – 2018/02

McAlpine JN, Anglesio M

Talhouk A, Hoang L, Britton H, Kale M.

Carraresi Foundation OVCARE Research Grant

Response to Primary Radiation in HPV-Associated and HPV-Independent Locally Advanced Vulvar Squamous Cell Cancers 

 C

 

$7,080 

2017/06 – 2019/06

Lily Proctor 

McAlpine J

Canadian Institute of Health Research

Multimodal optical imaging of the fallopian tubes 

 C

  Impact Grant

$378,675 

2017/10 – 2020/09

Lane P

MacAulay C, McAlpine JN

Canadian Cancer Society Research Institute 

The determinants of drug response in high grade serous ovarian cancer: a single cell population genetics approach 

 C

 Impact Grant

$1,250,000 

2018/01 – 2023/12

Shah S & McAlpine J

Aparicio S, Huntsman D, Bouchard-Cote A

Michael Smith Foundations for Health Research-REACH award

Biologically informed ovarian cancer prevention: Promoting education and awareness 

 C

 Current funding

$10,000 

2018/06 – 2019/06

McAlpine JN Huntsman DG

Lee, S

Michael Smith Foundations for Health Research-Innovation to commercialization (I2C)

Molecular classification for stratification and improved clinical management
of endometrial cancers

 C

 Current funding

$300,000 

2018/07 – 2020/07

McAlpine JN

Gilks CB, Aline T

Gynecologic Cancer Initiative-Clinical Trials Group

Molecular classification-drive care in Endometrial Cancer 

 C

 

$42,040 

2019/01 – 2021/01

McAlpine JN

Bachand F, Holloway C, Ko J, Kumar A, Kwon JS, Miller S, Raziee H, Talhouk A, Thompson E

Sumiko Kobayashi Marks Memorial OVCARE Research Grants (supported by VGH & UBC Hospital Foundation)

Refining the Clinical and Molecular Landscape of Vulvar Squamous Cell Carcinomas: Not a Single Disease Anymore 

 C

 

$19,678 

2019/01 – 2021/01

Hoang LN

McAlpine JN, Proctor L, Thompson E

Sumiko Kobayashi Marks Memorial OVCARE Research Grants supported by the VGH & UBC Hospital Foundation

Refining the Clinical and Molecular Landscape of Vulvar Squamous Cell Carcinomas: Not a Single Disease Anymore

 C

 

$19,678 

2019/06 – 2021/05

Hoang LN

McAlpine JN, Proctor L, Thompson E

Gynecologic Cancer Initiative-Clinical Trials Group

ProMisE-driven care in endometrial carcinoma-prospective trial 

 C

 

$104,000 

2019/07 – 2021/07

McAlpine JN

Holloway C, Bachand F, Kumar A, Thompson E, Ko J, Ye A, Raziee H, Kwon J, Talhouk A

Canadian Institute for Health Research-Project Grant

The effectiveness and cost effectiveness of opportunistic salpingectomy for ovarian
cancer prevention

 C

 

$302,176 

2019/07 – 2022/07

Hanley G

McAlpine JN Huntsman DG, Gilks CB, Kwon J, Talhouk A, Kotsopoulos J

Canadian Institutes for Health Research

Personalizing Prevention Strategies in Endometrial Cancer 

 C

 

$100,000 

2020/01 – 2021/01

Talhouk A

McAlpine JN, Kwon J, Tinker A, Hanley G, Miller D

Canadian Institute of Health Research

Pre-operative Risk Stratification in Endometrial Cancer to Inform Surgical Management 

 C

 

$263,925 

2020/07 – 2023/07

Talhouk A, McAlpine JN

Gilks CB, Huntsman DG, Hanley G

Selected Awards

University of British Columbia Faculty of Medicine- Mid-Career Excellence/Achievement, 2020

BC Cancer Foundation Clinician Scientist Award-Intertumoral heterogeneity in endometrial cancer $750,000 2016-2021.

University of British Columbia Faculty of Medicine -Excellence in Clinical or Applied Research 2016.

CIHR New Investigator Award. Genomic Disruption in High-Grade Serous Ovarian Carcinomas: Steady State or Continuous Drift? McAlpine JN $60,000/year 2012-2017.

Vancouver Coastal Health Research Institute In it For Life Mentored Clinical Scientist Award, 2008. PARP inhibitors in epithelial ovarian cancer: targeted molecular therapy in BRCA null phenotypes and mechanisms of resistance. $50,000/year 2008-2011.